Paclitaxel-Coated PTA Balloon Catheter

Ranger - For Consistent & Predictable Drug Delivery* 

The Ranger™ Drug-Coated Balloon (DCB) is designed to optimize drug transfer to the target vessel’s tissue through its TransPax coating, a proprietary formulation of Paclitaxel (PTx) and a citrate ester excipient.

Ranger is designed to provide coating durability* before and during deployment. Balanced hydrophobic and hydrophilic properties of TransPaxTM coating facilitates the balloon reaching the lesion with a therapeutic drug dose for your patient*.
Learn more about TransPax™

TransPax™ coating ensures targeted delivery of a consistent, therapeutic dose of the proven anti-proliferative drug, Paclitaxel*.

Ranger’s 2µg/mm² paclitaxel dose efficiently achieves sustained benefits of the drug* over time compared to other DCBs which use the higher 3µg/mm². 

Drug tissue levels

The TransPax™ coating is designed to be efficient in transferring drug to the vessel and achieves therapeutic drug tissue levels with only 2µg/mm² drug dosage vs some competitors 3µg/mm². 
Arterial tissue Paclitaxel concentrations over time of Ranger, and some competitors*.

Coating Transfer  

Balanced hydrophobic and hydrophilic properties allow efficient drug transfer to the vessel wall*.
Durability is one of the most important factors of a drug coating. If the coating is not durable, there is a risk that drug will come off the balloon during the journey to the lesion. Our excipient, a citrate ester, has a balance of hydrophilic and hydrophobic properties which supports coating integrity and adhesion to the balloon but also allows the coating to transfer to the vessel wall from the balloon during inflation. The selection of an excipient is critical to achieve desired tissue levels as the excipient modulates the release of the drug*. 
TransPax DCB integrity adherence hydratation

Enhanced coating integrity of TransPax™ technology*

The TransPaxTM coating was found to have good durability during hydration1

Minimized systemic loss*

Fewer drug particulates were lost with RangerTM DCB while delivering therapeutic arterial tissue Paclitaxel levels. In the bench top study, the Ranger PCB had fewer observable particles than either Lutonix or In.Pact Pacific. 
Lutonix MoxyTM
Medtronic In.Pact PacificTM
The Ranger™ coating technology is designed to deliver a therapeutic drug dose - consistently and efficiently* - to the lesion. Less drug is lost distally which provides the peace of mind of a predictable treatment. In this study, DCBs are delivered in the peripheral track model with fluid recirculation. Particulates lost downstream are collected with a Polycarbonate filter and shown here as green dots.**

Intuitive device handling

Ranger™ is equipped with a loading tool that protects the drug coating while handling and pushing through the introducer for increased intuitive use and minimized drug loss.